GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 213 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q3 2019. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $10,474,000 | +23.5% | 153,804 | -42.0% | 0.00% | 0.0% |
Q2 2022 | $8,479,000 | -15.3% | 265,366 | -8.2% | 0.00% | 0.0% |
Q1 2022 | $10,014,000 | +113.0% | 289,084 | +80.0% | 0.00% | +200.0% |
Q4 2021 | $4,701,000 | +69.3% | 160,595 | +47.3% | 0.00% | 0.0% |
Q3 2021 | $2,777,000 | +18.7% | 108,994 | +63.1% | 0.00% | 0.0% |
Q2 2021 | $2,340,000 | -31.4% | 66,829 | -20.2% | 0.00% | 0.0% |
Q1 2021 | $3,413,000 | -52.8% | 83,769 | -54.9% | 0.00% | -50.0% |
Q4 2020 | $7,228,000 | -5.0% | 185,834 | +34.7% | 0.00% | 0.0% |
Q3 2020 | $7,609,000 | -9.3% | 137,993 | +3.9% | 0.00% | 0.0% |
Q2 2020 | $8,385,000 | +51.8% | 132,832 | +22.8% | 0.00% | 0.0% |
Q1 2020 | $5,525,000 | -55.6% | 108,148 | -31.0% | 0.00% | -33.3% |
Q4 2019 | $12,456,000 | +45.5% | 156,688 | -11.2% | 0.00% | +50.0% |
Q3 2019 | $8,559,000 | -2.8% | 176,381 | +5.4% | 0.00% | -33.3% |
Q2 2019 | $8,802,000 | +19.5% | 167,344 | +20.3% | 0.00% | +50.0% |
Q1 2019 | $7,365,000 | +53.9% | 139,141 | +19.3% | 0.00% | 0.0% |
Q4 2018 | $4,787,000 | +17.6% | 116,616 | +8.8% | 0.00% | +100.0% |
Q3 2018 | $4,072,000 | -18.6% | 107,154 | -3.2% | 0.00% | 0.0% |
Q2 2018 | $5,003,000 | +1.4% | 110,684 | +8.4% | 0.00% | 0.0% |
Q1 2018 | $4,932,000 | +22.7% | 102,114 | -0.0% | 0.00% | 0.0% |
Q4 2017 | $4,019,000 | +24.7% | 102,121 | -1.7% | 0.00% | 0.0% |
Q3 2017 | $3,224,000 | -17.1% | 103,850 | -26.9% | 0.00% | 0.0% |
Q2 2017 | $3,887,000 | -12.5% | 142,090 | +17.9% | 0.00% | 0.0% |
Q1 2017 | $4,443,000 | +219.4% | 120,568 | +25.3% | 0.00% | – |
Q4 2016 | $1,391,000 | +191.0% | 96,205 | +363.8% | 0.00% | – |
Q3 2016 | $478,000 | +112.4% | 20,744 | +53.3% | 0.00% | – |
Q2 2016 | $225,000 | +257.1% | 13,532 | +241.5% | 0.00% | – |
Q1 2016 | $63,000 | -51.2% | 3,962 | -1.1% | 0.00% | – |
Q4 2015 | $129,000 | +12800.0% | 4,007 | +14210.7% | 0.00% | – |
Q3 2015 | $1,000 | – | 28 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |